Preoperative stereotactic radiosurgery for patients with 1–4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694)
Neuro-Oncology Practice · 13.09.2024 · 11 (5) · 593-603
DOI: 10.1093/nop/npae043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Practice, online erschienen am 08.05.2024. Verfasst von Namita Agrawal und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indianapolis, USA. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, IU Value Research grant, National Institutes of Health.
Abstract (Originalsprache)
Background
Stereotactic radiosurgery (SRS) following surgical resection is the standard of care for patients with symptomatic oligo brain metastasis (BM), however, it is associated with 10–15% local failure. Targeting a resection cavity is imprecise, thus preoperative radiosurgery where the target is well-defined may be superior, however, the efficacy of preoperative SRS has not yet been tested in a clinical trial.
Methods
We conducted a phase 2, single-arm trial of preoperative SRS followed by surgical resection in patients with 1–4 symptomatic oligo BMs (NCT03398694) with the primary objective of measuring 6-month local control (LC). SRS was delivered to all patients utilizing a gamma knife or linear accelerator as per RTOG-9005 dosing criteria [Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47(2):291–298] based on tumor diameter with the exception that the largest lesion diameter treated was 5 cm with 15 Gy with all SRS treatment given in single fraction dosing.
Results
The trial screened 50 patients, 48 patients were treated under the protocol and 32 patients completed the entire follow-up period. Of all the patients who completed the follow-up period, the primary endpoint of 6-month LC was 100% (95% CI: 0.891–1.000; P = .005). Secondary endpoints, presented as medians, were overall survival (17.6 months), progression-free survival (5.3 months), distant in-brain failure (40.8% at 1 year), leptomeningeal failure (4.8% at 1 year), and radiation necrosis (7.7% at 1 year).
Conclusions
Our data confirms superior local control in patients who received preoperative SRS when compared to historical controls. Further study with a larger randomized cohort of patients is warranted to fully understand the benefits of preoperative SRS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, Indianapolis, USA.
- Department of Neurosurgery, University of Wisconsin Madison School of Medicine and Public Health, Madison, Wisconsin, USA.
- Department of Clinical Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, Indianapolis, USA.
- Department of Biostatistics and Health Data Science, Indiana University School of Medicine and Richard M. Fairbanks School of Public Health, Indianapolis, Indianapolis, USA.
- Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, Indianapolis, USA.
- Goodman Campbell Brain and Spine Neurological Surgery, Indianapolis, Indianapolis, USA.
ORCID-Profile: Jack M Shireman, Yong Zang, Mahua Dey
Förderung
- NINDS NIH HHS
- IU Value Research grant
- National Institutes of Health
- National Institute of Neurological Disorders and Stroke
Zitieren
APA
Agrawal, N., Shireman, J. M., Shiue, K., Kamer, A., Boyd, L., Zang, Y., Mukherjee, N., Miller, J., Kulwin, C., Cohen-Gadol, A., Payner, T., Lin, C. T., Savage, J. J., Lane, B., Bohnstedt, B., Lautenschlaeger, T., Saito, N., Shah, M., Watson, G., & Dey, M. (2024). Preoperative stereotactic radiosurgery for patients with 1–4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694). Neuro-Oncology Practice, 11(5), 593-603. https://doi.org/10.1093/nop/npae043
Vancouver
Agrawal N, Shireman JM, Shiue K, Kamer A, Boyd L, Zang Y, et al. Preoperative stereotactic radiosurgery for patients with 1–4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694). Neuro-Oncology Practice. 2024;11(5):593-603. doi:10.1093/nop/npae043
BibTeX
@article{Agrawal2024,
author = {Agrawal, Namita and Shireman, Jack M and Shiue, Kevin and Kamer, Aaron and Boyd, LaKeisha and Zang, Yong and Mukherjee, Neel and Miller, James and Kulwin, Charles and Cohen-Gadol, Aaron and Payner, Troy and Lin, Chih-Ta and Savage, Jesse J and Lane, Brandon and Bohnstedt, Bradley and Lautenschlaeger, Tim and Saito, Naoyuki and Shah, Mitesh and Watson, Gordon and Dey, Mahua},
title = {Preoperative stereotactic radiosurgery for patients with 1–4 brain metastases: A single-arm phase 2 trial outcome analysis (NCT03398694)},
journal = {Neuro-Oncology Practice},
year = {2024},
volume = {11},
number = {5},
pages = {593--603},
doi = {10.1093/nop/npae043}
}
EUVIMED